News for IDEXX Laboratories, Inc. (IDXX.MX)

IDEXX Laboratories, Inc. (IDXX) has announced the election of Joseph L. (Jay) Hooley as an independent Class III Director, effective July 10, 2025. Mr. Hooley

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's

IDEXX Laboratories (IDXX) has appointed Joseph L. (Jay) Hooley to its Board of Directors, effective July 10, 2025. Jay Hooley brings extensive strategic

On July 2, 2025, Stifel maintained its "Hold" rating on IDEXX Laboratories, Inc. (IDXX), a leading company known for developing and offering diagnostic products

Quick Highlights: IDEXX Laboratories (IDXX) reports a robust Q2 2025 performance with significant gains. Wall Street forecasts suggest a stable outlook w

Two U.S. lawmakers are being called out after disclosing their stock purchases involving defense contractor L3Harris Technologies Inc. (NYSE: LHX), in the lead up to conflict with Iran, while serving on the Congressional Armed Services Committee.

For 1Q25, Macquarie Large Cap Growth Fund Institutional Class shares posted negative absolute returns but outperformed the Fund’s benchmark, the Russell 1000® Growth Index.

We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at where IDEXX Laboratories, Inc.

On May 19, 2025, Stifel analyst Jonathan Block decided to maintain a "Hold" rating for IDEXX Laboratories (IDXX), a prominent player in the diagnostic and IT so

IDEXX Laboratories, Inc. reports strong Q1 FY25 growth with 4.7% organic revenue. Click for my updated look at IDXX stock post earnings.

IDEXX Laboratories (IDXX) executives to participate in Stifel Jaws & Paws Conference on May 28, 2025. Company announces 2025 Investor Day scheduled for

IDEXX Laboratories, Inc. (IDXX) has made significant changes to its corporate structure following the 2025 Annual Meeting of Stockholders held on May 7, 2025.

Exploring the Investment Strategies of a Renowned Value Investor Wallace Weitz (Trades, Portfolio) recently submitted the 13F filing for the first quarter of 2

Baron Funds, an investment management firm, released its “Focused Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. Q1 was a difficult start to the year. The fund declined 7.95% (Institutional Shares) in the quarter, compared to the Russell 2500 Growth Index’s (the Benchmark) 10.80% return. Please spare […]

On May 5, 2025, Morgan Stanley analyst Erin Wright announced an update on IDEXX Laboratories (IDXX). The analyst has maintained the "Overweight" rating for the

Stifel has revised its price target for Idexx Laboratories (IDXX), increasing it from $420 to $460 while maintaining a Hold rating on the stock. According to th

Key Highlights: IDEXX Laboratories (IDXX) reports a strong Q1 2025 revenue of $998.4 million, marking a 4% increase year-over-year. Wall Street analysts

IDEXX Laboratories achieves 5% organic revenue growth in Q1 2025, powered by innovative product launches. Wall Street sets a favorable one-year price ta

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ETCompany ParticipantsAndrew Emerson - EVP, CFO and TreasurerJay...